Home » ImmunoGen Licenses Technology to Novartis in $245 Million Deal
ImmunoGen Licenses Technology to Novartis in $245 Million Deal
ImmunoGen Inc. has agreed to work with Novartis on targeted anticancer therapeutics developed using ImmunoGen’s Targeted Antibody Payload technology, in a deal potentially worth nearly $250 million — and potentially much more.
Mass High Tech
Mass High Tech
Upcoming Events
-
07May
-
14May
-
30May